Another long peptide pooled mutant-KRAS vaccine is being investigated in a phase I trial in combination with nivolumab and ipilimumab in patients with resected MMR-proficient colorectal cancer and pancreatic cancer (NCT04117087). The gene discussed is KRAS; the disease is pancreatic neoplasm.